Ind-Ra maintains neutral outlook for Indian pharmaceutical sector for FY24
![](https://portfolio.investmentguruindia.com/investmentguruimages/upload/post/2023/04/cc13ec0e54be002097c4b428251e6742.jpg)
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Maintaining a neutral outlook for the Indian pharmaceutical sector for FY24, credit rating agency, Ic and Research (Ind-Ra) has said that the Indian pharmaceuticals market (IPM) is likely to grow 10%-11% year on year (yoy) in FY24 (FY22: 14.5% yoy; FY23: 9.3% yoy).
The agency also expects a muted performance in the US generic market due to a high single-digit price deflation (9MFY23 and FY22: high single digit to low double digit). As per the agency, the Indian active pharmaceuticals ingredient (API) suppliers witnessed weak growth of negative 8.1% yoy in FY22 (FY21: 19.2% yoy), due to inventory destocking and high base last year, while a recovery was seen in 9MFY23 (up 5.6% yoy).
Ind-Ra further noted that the API business of selected companies is expected to report high single-digit growth in FY24 due to a demand uptick; the overall revenue growth for them is also expected at 9%-10% yoy, given their optimised operating costs, a moderation in the US price erosion, a softening of raw material and other cost (logistic/freight). This will lead to a healthy EBITDA margin performance (around 21%) in FY24 (FY22: 20.1; FY21: 23.0%; 9MFY23: 20.3%).c
![](https://portfolio.investmentguruindia.com/uploads/news/port57.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/Tradebulls Securities.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/Broker _15.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/geojit market watch.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/Geojit Financial Services.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/mobile57.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/Nirmal bang.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/health57.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/Geojit Financial Services.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/Nirmal bang.jpg)
Tag News
![](https://portfolio.investmentguruindia.com/investmentguruimages/upload/post/2023/09/c5541407585e9dfdc52f905c92d59e61.jpg)
Monthly Debt Market Update, September 2023: CareEdge Ratings
![Quote on RBI decision to discontinue the incremental cash reserve ratio (CRR) By Dr. Manoranjan Sharma, Infomerics Ratings](https://portfolio.investmentguruindia.com/investmentguruimages/upload/post/2023/09/3fb5395769079c26d9056714d034c581.jpg)
![Governance mechanism, customer-centricity can help in fintech ecosystem sustainable growth: Ajay Chaudhary](https://portfolio.investmentguruindia.com/investmentguruimages/upload/post/2023/09/07e25a74a16d5c092d179215565d0295.jpg)
![3 Centres of Excellence set up by TIDCO finding good traction: Tamil Nadu Minister](https://portfolio.investmentguruindia.com/investmentguruimages/upload/post/2023/09/e6ff15c8d3a72074f69cb881ab6584e7.jpg)